risperidone and Sensitivity and Specificity studies

Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.

Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)

Research Excerpts

Excerpt	Relevance	Reference
"In newly admitted patients with acute schizophrenia, non-response to risperidone using CGI-I at 2 weeks can predict subsequent response."	9.15	Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. ( Ashizawa, Y; Hamakawa, H; Hatta, K; Hayakawa, T; Hayashi, N; Hirata, T; Ito, S; Nakamura, H; Nakase, R; Otachi, T; Sawa, Y; Sudo, Y; Takebayashi, H; Usui, C, 2011)
" IL-6 levels were compared in patients with schizophrenia before and after risperidone treatment."	9.05	Effects of risperidone on blood levels of interleukin-6 in schizophrenia: A meta-analysis. ( Feng, Z; Hao, W; Liu, Z; Long, Q; Ma, Y; Teng, Z; You, X; Zeng, Y; Zhang, W; Zhang, Y, 2020)
"In newly admitted patients with acute schizophrenia, non-response to risperidone using CGI-I at 2 weeks can predict subsequent response."	5.15	Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. ( Ashizawa, Y; Hamakawa, H; Hatta, K; Hayakawa, T; Hayashi, N; Hirata, T; Ito, S; Nakamura, H; Nakase, R; Otachi, T; Sawa, Y; Sudo, Y; Takebayashi, H; Usui, C, 2011)
"One hundred twenty-three inpatients with acutely exacerbated schizophrenia were given optimal therapy of risperidone, a commonly used second-generation antipsychotic agent."	5.12	Optimizing early prediction for antipsychotic response in schizophrenia. ( Chang, YC; Huang, CL; Lane, HY; Yang, KH, 2006)
" IL-6 levels were compared in patients with schizophrenia before and after risperidone treatment."	5.05	Effects of risperidone on blood levels of interleukin-6 in schizophrenia: A meta-analysis. ( Feng, Z; Hao, W; Liu, Z; Long, Q; Ma, Y; Teng, Z; You, X; Zeng, Y; Zhang, W; Zhang, Y, 2020)
"Adult Maryland Medicaid patients with schizophrenia were categorized based on initial atypical antipsychotic drug received: aripiprazole (n=446); olanzapine (n=1705); quetiapine (n=1467); risperidone (n=1580); and ziprasidone (n=700)."	3.74	Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. ( Cuffel, BJ; Loebel, AD; Mullins, CD; Naradzay, J; Obeidat, NA, 2008)

Research

Studies (33)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Mean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Abnormal Involuntary Movement Scale (AIMS)- Non-Global Total Score

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (3.03)	18.2507
2000's	18 (54.55)	29.6817
2010's	13 (39.39)	24.3611
2020's	1 (3.03)	2.80

Authors	Studies
Diamandis, P	1
Wildenhain, J	1
Clarke, ID	1
Sacher, AG	1
Graham, J	1
Bellows, DS	1
Ling, EK	1
Ward, RJ	1
Jamieson, LG	1
Tyers, M	1
Dirks, PB	1
Feng, Z	1
Zhang, Y	2
You, X	1
Zhang, W	1
Ma, Y	1
Long, Q	1
Liu, Z	1
Hao, W	1
Zeng, Y	1
Teng, Z	1
Østergaard, SD	1
Foldager, L	1
Mors, O	1
Bech, P	1
Correll, CU	1
Tsuboi, T	1
Bies, RR	1
Suzuki, T	1
Mamo, DC	1
Pollock, BG	1
Graff-Guerrero, A	1
Mimura, M	1
Uchida, H	1
Leucht, S	1
Zhao, J	1
Mannheimer, B	2
Holm, J	1
Koukel, L	1
Bertilsson, L	1
Osby, U	1
Eliasson, E	2
Pasternak, B	1
Svanström, H	1
Ranthe, MF	1
Melbye, M	1
Hviid, A	1
Haslemo, T	1
Lindh, JD	1
Molden, E	1
De Meulder, M	1
Remmerie, BM	1
de Vries, R	1
Sips, LL	1
Boom, S	1
Hooijschuur, EW	1
van de Merbel, NC	1
Timmerman, PM	1
Jones, T	1
Van Breda, K	1
Charles, B	1
Dean, AJ	1
McDermott, BM	1
Norris, R	1
Kinon, BJ	1
Chen, L	1
Ascher-Svanum, H	1
Stauffer, VL	1
Kollack-Walker, S	1
Zhou, W	1
Kapur, S	1
Kane, JM	1
Saracino, MA	1
de Palma, A	1
Boncompagni, G	2
Raggi, MA	2
West, AE	1
Celio, CI	1
Henry, DB	1
Pavuluri, MN	1
Mandrioli, R	1
Mercolini, L	1
Lateana, D	1
Hatta, K	1
Otachi, T	1
Sudo, Y	1
Hayakawa, T	1
Ashizawa, Y	1
Takebayashi, H	1
Hayashi, N	1
Hamakawa, H	1
Ito, S	1
Nakase, R	1
Usui, C	1
Nakamura, H	1
Hirata, T	1
Sawa, Y	1
Cai, HL	1
Zhu, RH	1
Li, HD	1
Zhang, J	1
Li, LF	1
de Jesus, LI	1
Albuquerque, NC	1
Borges, KB	1
Simões, RA	1
Calixto, LA	1
Furtado, NA	1
de Gaitani, CM	1
Pupo, MT	1
de Oliveira, AR	1
Flarakos, J	1
Luo, W	1
Aman, M	1
Svinarov, D	1
Gerber, N	1
Vouros, P	1
Zhou, Z	1
Li, X	1
Li, K	1
Xie, Z	1
Cheng, Z	1
Peng, W	1
Wang, F	1
Zhu, R	1
Li, H	1
Song, Z	1
Wang, C	1
Bobes, J	1
Cañas, F	1
Rejas, J	1
Mackell, J	1
Treuer, T	1
Basson, BR	1
Bhatt, J	1
Subbaiah, G	1
Singh, S	1
Chang, YC	1
Lane, HY	1
Yang, KH	1
Huang, CL	1
Cabovska, B	1
Cox, SL	1
Vinks, AA	1
Ito, T	1
Meguro, K	1
Akanuma, K	1
Meguro, M	1
Lee, E	1
Kasuya, M	1
Ishii, H	1
Mori, E	1
Mullins, CD	1
Obeidat, NA	1
Cuffel, BJ	1
Naradzay, J	1
Loebel, AD	1
Lu, Y	1
Tang, X	1
Cui, Y	1
Qin, F	1
Lu, X	1
Nagasaki, T	1
Ohkubo, T	1
Sugawara, K	1
Yasui, N	1
Furukori, H	1
Kaneko, S	1
Aravagiri, M	1
Marder, SR	1
Avenoso, A	1
Facciolà, G	1
Salemi, M	1
Spina, E	1
Scharfstein, D	1
Robins, JM	1
Eddings, W	1
Rotnitzky, A	1
Titier, K	1
Déridet, E	1
Cardone, E	1
Abouelfath, A	1
Moore, N	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)[NCT00014001]	Phase 4	1,600 participants	Interventional	2000-12-31	Completed
Predicting Response to Risperidone Treatment Through Identification of Early-onset of Antipsychotic Drug Action in Schizophrenia.[NCT00337662]	Phase 4	628 participants (Actual)	Interventional	2006-05-31	Completed
CYP2D6 PHARMACOGENETICS IN RISPERIDONE-TREATED CHILDREN AND ADOLESCENTS WITH PSYCHIATRIC OR NEURODEVELOPMENTAL DISORDERS[NCT00783783]		47 participants (Actual)	Observational	2008-11-30	Completed
Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva[NCT00395499]		19 participants	Observational	2001-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

A 12-item instrument assesses observed abnormal movements in different parts of body. Ten items are scored in a 5-point scale (0 = none/normal, 4 = severe) which evaluates abnormal movements in three main anatomic areas (orofacial area, extremities, and trunk). Two items are yes/no questions regarding dentures. Total scores range from 0 to 42. (NCT00337662)
Timeframe: Week 2 to Week 12

Mean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Barnes Akathisia Rating Scale - Total Score

Intervention	units on a scale (Mean)
NEO-OLZ	-0.38
NEO-RIS	0.11
EO-RIS	-0.16

Evaluates akathisia associated with use of antipsychotic medications, includes objective and subjective component plus global impression rating for overall disorder. Components rated on scale of 0 to 3 for objective and subjective items and 0 to 5 for global clinical assessment, for total score of 0 (absence of akathisia) to 11 (severe akathisia). (NCT00337662)
Timeframe: Week 2 to Week 12

Mean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Modified Simpson-Angus Scale

Intervention	units on a scale (Mean)
NEO-OLZ	-0.31
NEO-RIS	-0.13
EO-RIS	-0.24

Measures neuroleptic-induced parkinsonism. Total score consists of the sum of 10 items: 7 items (items 1, 3, 4, 7, 8, 9, 10) rated on a 4-point severity scale where 0=normal and 4=extreme, and 3 items (items 2, 5, 6) rated on a 2-point severity scale where 0=normal and 2=definitely abnormal/present. The total score ranges from 0 to 34. (NCT00337662)
Timeframe: Week 2 to Week 12

Changes From Study Period II Baseline (Week 0) to Weeks 3, 4, 6, 8, and 12 in Positive and Negative Syndrome Scale (PANSS) Total Score in Early Onset Response and Not Early Onset Response-Risperidone Patients

Intervention	units on a scale (Mean)
NEO-OLZ	-0.06
NEO-RIS	-0.03
EO-RIS	-0.02

Assesses positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. Scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Sum of 30 items is PANSS total score and ranges from 30 to 210. Change = time point - single-blind baseline (Week 0). (NCT00337662)
Timeframe: Weeks 0, 3, 4, 6, 8, 12

Changes From Study Period III Baseline (Week 2) to Weeks 3, 4, 6, 8, and 12 in Positive and Negative Syndrome Scale Total Score in Not Early Onset Response-Risperidone and Not Early Onset Response-Olanzapine Patients

Intervention	units on a scale (Least Squares Mean)
	Change from Week 0 to Week 3	Change from Week 0 to Week 4	Change from Week 0 to Week 6	Change from Week 0 to Week 8	Change from Week 0 to Week 12
EO-RIS	-30.80	-32.53	-32.90	-34.10	-35.09
NEO-RIS	-11.90	-14.81	-16.23	-18.10	-18.62

Assesses positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. Scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Sum of 30 items is PANSS total score and ranges from 30 to 210. Change = time point - double-blind baseline (Week 2). (NCT00337662)
Timeframe: Weeks 2, 3, 4, 6, 8, 12

Number of Participants in the Early Onset and Not Early Onset-Risperidone Groups Who Show a 50% or Greater Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline or Meet 'a Priori' Specified Criteria for Remission

Intervention	units on a scale (Least Squares Mean)
	Change from Week 2 to Week 3	Change from Week 2 to Week 4	Change from Week 2 to Week 6	Change from Week 2 to Week 8	Change from Week 2 to Week 12
NEO-OLZ	-5.85	-9.67	-13.06	-14.73	-17.02
NEO-RIS	-6.94	-9.82	-11.25	-13.13	-13.53

'a priori' specified criteria for remission defined as a score of 3 (mild), 2 (minimal), or 1 (absent) on all of the following 8 PANSS items: delusions, conceptual disorganization, hallucinatory behavior, unusual thought content, mannerisms and posturing, blunted effect, passive/apathetic withdrawal, lack of spontaneity and flow of conversation. (NCT00337662)
Timeframe: Week 0 to Week 12

Number of Participants in the Not Early Onset-Risperidone and Not Early Onset-Olanzapine Groups Who Show a 50% or Greater Reduction in Positive and Negative Syndrome Scale Total Score From Baseline or Meet 'a Priori' Specified Criteria for Remission

Intervention	participants (Number)
	>=50% Reduction - Yes	>=50% Reduction - No
EO-RIS	87	51
NEO-RIS	67	122

Number of Participants With Psychiatric Hospitalizations in the Early Onset and Not Early Onset-Risperidone Groups

Intervention	participants (Number)
	>=50% Reduction - Yes	>=50% Reduction - No
NEO-OLZ	67	112
NEO-RIS	67	122

Psychiatric Hospitalizations were measured by the Modified Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ) from which it could be determined the number of patients with a psychiatric episode that required an overnight stay in a hospital. (NCT00337662)
Timeframe: Week 2 to Week 12

Number of Participants With Treatment-Emergent Abnormal Fasting Laboratory Analytes Reported in >=2% of All Participants

Intervention	participants (Number)
	Required overnight stay in hospital: Yes	Required overnight stay in hospital: No
EO-RIS	10	127
NEO-RIS	9	175

Number of participants who experienced abnormal fasting laboratory values at any time during Study Period III. Laboratory reference ranges are dependent on the patient's gender, origin, and age. (NCT00337662)
Timeframe: Week 2 to Week 12

The Number of Participants in the Early Onset (EO) and Not Early Onset-Risperidone (NEO-RIS) Groups Who Show a 20% or Greater Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score

Intervention	participants (Number)
	Low total bilirubin	High creatine phosphokinase	High creatinine	High hemoglobin A1c	Low sodium	High prolactin
EO-RIS	2	5	3	2	4	7
NEO-OLZ	5	6	2	6	4	7
NEO-RIS	3	1	4	7	4	8

The number of participants who experienced a 20% or greater reduction in their PANSS Total score during the 12 weeks they were on risperidone. (NCT00337662)
Timeframe: Week 0 to Week 12

The Number of Participants in the Not Early Onset-Risperidone (NEO-RIS) and Not Early Onset-Olanzapine (NEO-OLZ) Groups Who Show a 20% or Greater Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score

Intervention	participants (Number)
	>=20% Reduction - Yes	>=20% Reduction - No
EO-RIS	119	19
NEO-RIS	94	95

The number of not early onset participants who experienced a 20% or greater reduction in PANSS Total Score at any time during the 12 weeks of combined Study Period II and Study Period III. (NCT00337662)
Timeframe: Week 0 to Week 12

Vital Signs - Change From Baseline to 10 Week Endpoint in Standing Diastolic Blood Pressure

Intervention	participants (Number)
	>=20% Reduction - Yes	>=20% Reduction - No
NEO-OLZ	94	85
NEO-RIS	94	95

Change from Study Period III baseline to endpoint in standing blood pressure. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 and Week 12

Vital Signs - Change From Baseline to 10 Week Endpoint in Standing Mean Arterial Pressure

Intervention	mm Hg (Mean)
	Baseline	Change from Baseline
EO-RIS	80.29	-1.73
NEO-OLZ	78.69	1.01
NEO-RIS	78.57	-0.20

Change from Study Period III baseline to endpoint in standing mean arterial pressure. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 and Week 12

Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Body Mass Index

Intervention	mm Hg (Mean)
	Baseline	Change from Baseline
EO-RIS	94.60	-1.94
NEO-OLZ	93.53	0.68
NEO-RIS	93.81	-0.58

Body mass index is an estimate of body fat based on body weight divided by height squared. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 to Week 12

Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Body Weight

Intervention	kilogram per square meter (Mean)
	Baseline	Change from Baseline
EO-RIS	31.13	0.10
NEO-OLZ	29.97	0.63
NEO-RIS	31.05	0.43

Change from Study Period III baseline to endpoint in body weight. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 and Week 12

Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Sitting Pulse Rate

Intervention	kilograms (Mean)
	Baseline	Change from Baseline
EO-RIS	90.67	0.30
NEO-OLZ	88.28	1.85
NEO-RIS	90.25	1.29

Changes from Study Period III baseline to endpoint in sitting pulse rate. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 and Week 12

Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Standing Pulse Rate

Intervention	beats per minute (Mean)
	Baseline	Change from Baseline
EO-RIS	77.90	-0.94
NEO-OLZ	80.49	-0.98
NEO-RIS	80.84	-2.52

Change from Study Period III baseline to endpoint in standing pulse rate. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 and Week 12

Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Standing Systolic Blood Pressure

Intervention	beats per minute (Mean)
	Baseline	Change from Baseline
EO-RIS	82.39	-0.56
NEO-OLZ	85.57	-1.13
NEO-RIS	85.32	-2.05

Change from Study Period III baseline to endpoint in standing systolic blood pressure. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 and Week 12

Article	Year
Effects of risperidone on blood levels of interleukin-6 in schizophrenia: A meta-analysis. Medicine, 2020, Volume: 99, Issue:15 Topics: Adult; Antipsychotic Agents; Biomarkers; Female; Follow-Up Studies; Humans; Interleukin-6; Male; Mid	2020
Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program. Journal of psychopharmacology (Oxford, England), 2014, Volume: 28, Issue:4 Topics: Antipsychotic Agents; Benzodiazepines; Dibenzocycloheptenes; Haloperidol; Heterocyclic Compounds, 4	2014

Article	Year
The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia. Acta psychiatrica Scandinavica, 2018, Volume: 138, Issue:5 Topics: Antipsychotic Agents; Clozapine; Cross-Sectional Studies; Humans; Olanzapine; Outcome Assessment, He	2018
Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Progress in neuro-psychopharmacology & biological psychiatry, 2013, Aug-01, Volume: 45 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Hyperprolactinemia;	2013
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2010, Volume: 35, Issue:2 Topics: Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Administration Schedule; Female; Fo	2010
Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. Schizophrenia research, 2011, Volume: 128, Issue:1-3 Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug	2011
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain. Progress in neuro-psychopharmacology & biological psychiatry, 2004, Volume: 28, Issue:8 Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Dyskinesia, Drug-Induced; Follow-Up St	2004
Optimizing early prediction for antipsychotic response in schizophrenia. Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:6 Topics: Adolescent; Adult; Antipsychotic Agents; Area Under Curve; Female; Humans; Logistic Models; Male; Mi	2006
Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia. Journal of pharmaceutical and biomedical analysis, 1999, Volume: 19, Issue:3-4 Topics: Adult; Aged; Antipsychotic Agents; Chromatography, High Pressure Liquid; Drug Administration Schedul	1999

Article	Year
Chemical genetics reveals a complex functional ground state of neural stem cells. Nature chemical biology, 2007, Volume: 3, Issue:5 Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic	2007
Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients. European journal of clinical pharmacology, 2014, Volume: 70, Issue:6 Topics: Adult; Aged; Antipsychotic Agents; Area Under Curve; Biomarkers; Cytochrome P-450 CYP2D6; Female; Ge	2014
Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults: a nationwide register-based cohort study in Denmark. CNS drugs, 2014, Volume: 28, Issue:10 Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cardiovascular Disea	2014
Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype. Therapeutic drug monitoring, 2016, Volume: 38, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antipsychotic	2016
Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2008, Jul-01, Volume: 870, Issue:1 Topics: Chromatography, Liquid; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Risperidone; Sensit	2008
Determination of risperidone and 9-Hydroxyrisperidone using HPLC, in plasma of children and adolescents with emotional and behavioural disorders. Biomedical chromatography : BMC, 2009, Volume: 23, Issue:9 Topics: Adolescent; Antipsychotic Agents; Child; Chromatography, High Pressure Liquid; Female; Humans; Isoxa	2009
Analysis of risperidone and its metabolite in plasma and saliva by LC with coulometric detection and a novel MEPS procedure. Talanta, 2010, Jun-15, Volume: 81, Issue:4-5 Topics: Adult; Calibration; Chemistry Techniques, Analytical; Chromatography, Liquid; Colorimetry; Female; H	2010
Child Mania Rating Scale-Parent Version: a valid measure of symptom change due to pharmacotherapy. Journal of affective disorders, 2011, Volume: 128, Issue:1-2 Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Child; Diagnosis, Differential; Dopamine Antagonists	2011
Analysis of risperidone and 9-hydroxyrisperidone in human plasma, urine and saliva by MEPS-LC-UV. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2011, Jan-15, Volume: 879, Issue:2 Topics: Chromatography, Liquid; Humans; Isoxazoles; Linear Models; Paliperidone Palmitate; Psychotic Disorde	2011
MultiSimplex optimization of chromatographic separation and dansyl derivatization conditions in the ultra performance liquid chromatography-tandem mass spectrometry analysis of risperidone, 9-hydroxyrisperidone, monoamine and amino acid neurotransmitters Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2011, Jul-01, Volume: 879, Issue:21 Topics: Biogenic Monoamines; Case-Control Studies; Chromatography, High Pressure Liquid; Dansyl Compounds; H	2011
Enantioselective fungal biotransformation of risperidone in liquid culture medium by capillary electrophoresis and hollow fiber liquid-phase microextraction. Electrophoresis, 2011, Volume: 32, Issue:19 Topics: Analysis of Variance; Biotransformation; Electrophoresis, Capillary; Hydrogen-Ion Concentration; Iso	2011
Quantification of risperidone and 9-hydroxyrisperidone in plasma and saliva from adult and pediatric patients by liquid chromatography-mass spectrometry. Journal of chromatography. A, 2004, Feb-13, Volume: 1026, Issue:1-2 Topics: Adult; Calibration; Chemical Precipitation; Child; Chromatography, Liquid; Humans; Isoxazoles; Mass	2004
Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2004, Apr-05, Volume: 802, Issue:2 Topics: Antipsychotic Agents; Benzodiazepines; Calibration; Chromatography, High Pressure Liquid; Clozapine;	2004
Sensitive chemiluminescence assay for risperidone in pharmaceutical preparations. Journal of pharmaceutical and biomedical analysis, 2004, Nov-15, Volume: 36, Issue:3 Topics: Luminescent Measurements; Pharmaceutical Preparations; Risperidone; Sensitivity and Specificity	2004
Is there a real difference between the first onset of efficacy for atypical antipsychotic monotherapies in acute bipolar mania? The Journal of clinical psychiatry, 2005, Volume: 66, Issue:10 Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clinical Trials as Topic; Human	2005
Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. Rapid communications in mass spectrometry : RCM, 2006, Volume: 20, Issue:14 Topics: Administration, Oral; Antipsychotic Agents; Chromatography, High Pressure Liquid; Humans; Isoxazoles	2006
Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2007, Jun-01, Volume: 852, Issue:1-2 Topics: Child; Chromatography, Liquid; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Reference St	2007
Behavioral and psychological symptoms assessed with the BEHAVE-AD-FW are differentially associated with cognitive dysfunction in Alzheimer's disease. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2007, Volume: 14, Issue:9 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Behavioral Symptoms; Cognition Dis	2007
Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophrenia research, 2008, Volume: 98, Issue:1-3 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Female; Follow-Up Studies	2008
In vivo evaluation of risperidone-SAIB in situ system as a sustained release delivery system in rats. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2008, Volume: 68, Issue:2 Topics: Animals; Antipsychotic Agents; Area Under Curve; Delayed-Action Preparations; Male; Particle Size; R	2008
Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry. Journal of mass spectrometry : JMS, 2000, Volume: 35, Issue:6 Topics: Animals; Antipsychotic Agents; Chromatography, Liquid; Humans; Isoxazoles; Mass Spectrometry; Palipe	2000
Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. Journal of chromatography. B, Biomedical sciences and applications, 2000, Sep-15, Volume: 746, Issue:2 Topics: Antipsychotic Agents; Chromatography, High Pressure Liquid; Humans; Isoxazoles; Paliperidone Palmita	2000
Inference in randomized studies with informative censoring and discrete time-to-event endpoints. Biometrics, 2001, Volume: 57, Issue:2 Topics: Antipsychotic Agents; Biometry; Computer Simulation; Humans; Models, Statistical; Placebos; Psychoti	2001
Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in plasma after overdose. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2002, Jun-05, Volume: 772, Issue:2 Topics: Antipsychotic Agents; Chromatography, High Pressure Liquid; Drug Overdose; Humans; Isoxazoles; Palip	2002

risperidone and Sensitivity and Specificity